In June 2025, the EMA's CHMP adopted a positive opinion recommending a new indication for Imbruvica in combination with doxorubicin for the treatment of adult patients with previously untreated mantle cell lymphoma eligible for autologous stem cell transplantation. This development reflects ongoing advancements in combination therapies involving doxorubicin.
In October 2024, the FDA updated Import Alert 66-66, addressing APIs that appear to be misbranded under section 502(f)(1) of the FD&C Act. While not specific to doxorubicin, this alert emphasizes the importance of compliance with labeling requirements for APIs intended for the U.S. market.
In April 2019, the EMA recommended the withdrawal of the marketing authorization for Lartruvo (olaratumab) in combination with doxorubicin, as the ANNOUNCE study concluded that the combination did not prolong the lives of patients with soft tissue sarcoma more than doxorubicin alone. This decision underscores the necessity of robust clinical evidence for combination therapies.
In September 2025, the marketing authorization for Celdoxome pegylated liposomal (doxorubicin) ceased to be valid in the EU, as the product had not been marketed within three years of its initial authorization. This highlights the importance of timely market entry following regulatory approval.
In March 2020, Laboratorios Tillomed Spain S.L.U. withdrew its application for a marketing authorization of Doxorubicin Hydrochloride Tillomed, intended for the treatment of various cancers. The withdrawal was due to the company's inability to address the CHMP's major objections within the available timeframe. This reflects the challenges companies may face in meeting stringent regulatory requirements.
These developments illustrate the dynamic regulatory landscape surrounding doxorubicin, emphasizing the need for manufacturers and exporters to stay informed and compliant with evolving standards and requirements.
